Impact of COVID-19 Infection on Clinical Outcomes Among Patients With Acute Decompensated Heart Failure: A Nationwide Analysis.

Autor: Fatuyi M; Department of Medicine, TriHealth Good Samaritan Hospital Program, Cincinnati, OH. Electronic address: michaelfatuyi@gmail.com., Amoah J; Department of Medicine, Case Western Reserve University Hospital, Cleveland, OH., Egbuchiem H; Department of Medicine, Case Western Reserve University Hospital, Cleveland, OH., Antia A; Department of Medicine, Lincoln Medical Center, Bronx, NY., Akinti S; Department of Medicine, Brookdale University Hospital, medical center, Queens, NY., Mararenko A; Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ., Alzamara M; Department of Medicine, TriHealth Good Samaritan Hospital Program, Cincinnati, OH., Bhatia A; Department of Cardiology, Heart and Vascular Institute, The Christ Hospital Health Network,Cincinnati, OH.
Jazyk: angličtina
Zdroj: Current problems in cardiology [Curr Probl Cardiol] 2023 Nov; Vol. 48 (11), pp. 101908. Date of Electronic Publication: 2023 Jul 01.
DOI: 10.1016/j.cpcardiol.2023.101908
Abstrakt: Heart Failure (HF) is a common comorbidity in the United state. COVID-19 infection has shown worse clinical outcomes among heart failure patients; however, there is limited evidence on the impact of COVID-19 infection on the subset of HF. Hence, we aimed to investigate the clinical outcomes in patients hospitalized with COVID-19 infection without HF vs concomitant COVID-19 infection with Acute Decompensated Heart Failure with Preserved Ejection Fraction (AD-HFpEF) vs concomitant COVID-19 Infection with Acute Decompensated Heart Failure with Reduced Ejection Fraction (AD-HFrEF) using a large dataset illustrating a real word analysis. A retrospective study design of hospitalizations using the National Inpatient Sample (NIS) database registry 2020 with a principal diagnosis of adult patients (≥18 years) hospitalized with COVID-19 infection as principal diagnosis using ICD-10 codes stratified to COVID-19 infection without HF vs COVID-19 infection with AD-HFpEF vs COVID-19 infection with AD-HFrEF. The primary outcome was in-hospital mortality. Multivariate logistic, linear, poisson, and Cox regression models were used for analysis. A P-value < 0.05 was considered statistically significant. A total of 1,050,045 COVID-19 infection cases were included in this study, out of which 1,007,860 (98.98%) had only COVID-19 infection without HF, while 20,550 (1.96%) had COVID-19 infection with Acute Decompensated HFpEF, and 21,675 (2.06%) had COVID-19 infection with Acute Decompensated HFrEF. Our study shows that patients with COVID-19 infection and AD-HFrEF had the highest in-hospital mortality rate (25.4%). Using COVID-19 infection without HF with a mortality of 10.6% as a reference, COVID-19 infection with AD-HFpEF with a 22.5% mortality rate (95% CI 2.3-2.6, aOR; 2.4) and COVID-19 infection with AD-HFrEF with 25.4% mortality rate (95% CI 2.7-3.1, aOR; 2.9). Acute Decompensated HF with concurrent COVID-19 infection is associated with higher in-hospital mortality, with higher in-hospital mortality outcome observed among COVID 19 infection with concurrent AD-HFrEF.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: